India, May 11 -- Galectin Therapeutics Inc. (GALT), a clinical-stage biotechnology company, on Monday published promising results from the Phase 2b NAVIGATE trial for belapectin in treating MASH cirrhosis and portal hypertension in AASLD flagship journal Hepatology.
Metabolic dysfunction-related steatohepatitis (MASH) can lead to cirrhosis of the liver tissue and increased blood pressure in the system of veins carrying blood from digestive organs to the liver, also known as portal hypertension.
Belapectin is an investigational drug that inhibits galectin-3, a key mediator of fibrosis and inflammation, to treat complications from MASH cirrhosis. It was previously granted Fast Track designation by the U.S. Food and Drug Administration (FDA)...